Project Grant K00CA284284
Award Date
1/1/25
Completion Date
12/31/28
Dollars Obligated
$101K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $154,642 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research organization in New York. The goal of this 2-year award, effective March 1, 2025, is to systematically elucidate the evolving immunopeptidome from normal colon, primary tumor, and metastatic colorectal cancer lesions using patient-derived organoid models. The research aims to identify...
This $689,914 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to delineate the mechanisms of ferroptosis evasion in non-small cell lung cancer (NSCLC) tumors harboring co-mutations in STK11 and KEAP1. The research aims to establish ferroptosis as a potential therapeutic target in this aggressive subtype of lung cancer, which has extremely poor prognosis (median overall survival of only 7.3 months). Specifically, the...
This Project Grant award from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) provides $583,127 to the Sloan-Kettering Institute for Cancer Research to investigate the mechanisms by which SMARCA4 deficiency promotes metastasis in lung adenocarcinoma (LUAD). The research aims to elucidate how the ROR2/p-GSK3Bβ signaling pathway regulates transcription and metastasis in SMARCA4-deficient LUAD, and to evaluate the therapeutic potential of targeting ROR2 to...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $158,020 to the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair mechanisms in the persistence of cancer cells and the development of acquired drug resistance. The research aims to:
Examine persistence and mutagenic DNA repair in BRCA1/2-mutant cancer cells treated with PARP inhibitors.
Investigate mechanisms of mutagenic...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $144,056 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research aimed at quantitatively predicting drug-resistant kinase mutations in cancer. The overarching goal is to develop computational models that can forecast the impact of clinically observed kinase mutations on inhibitor resistance, sensitivity, and susceptibility. This will involve using binding...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding a research project to investigate mechanisms of immune therapy resistance. The $620,820 award to The General Hospital Corporation (Massachusetts General Hospital) supports studies to: 1) understand the molecular regulation and transcriptional effects of the CREB5 transcription factor, which was identified as a driver of immune evasion; 2) examine CREB5-interacting proteins...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) will support a comprehensive, spatiotemporal analysis of cancer metastasis in small cell lung cancer (SCLC) at Columbia University. The key objectives are to: 1) Map the evolutionary dynamics and trajectories of SCLC metastasis using a novel lineage tracing mouse model; 2) Dissect the spatial context and cellular composition of the pro-metastatic tumor...
The National Cancer Institute (NCI) awarded a $703,410 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to New York University (NYU) School of Medicine. The grant, awarded on January 16, 2025, supports a comprehensive research program aimed at understanding and disrupting the adenocarcinoma-to-squamous-cell transition, a cellular plasticity mechanism that enables resistance to KRAS inhibitor therapies in non-small cell lung cancer.
The research involves conducting a...
The University of Chicago was awarded a $230,010 Project Grant by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop innovative methods and tools to investigate the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The research strategy will integrate human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing...